Last updated: February 20, 2026
What is NDC 69452-0395?
NDC 69452-0395 refers to a specific pharmaceutical product listed under the National Drug Code (NDC) directory. This code identifies the drug's manufacturer, formulation, and packaging, facilitating tracking and reimbursement.
Based on the NDC directory, NDC 69452-0395 corresponds to Sovaldi (sofosbuvir) 400 mg tablets, marketed by Gilead Sciences. Sofosbuvir is a nucleotide analog inhibitor used primarily for treating hepatitis C virus (HCV) infections.
Market Overview
Current Market Status
The hepatitis C treatment market has undergone significant shifts over the past decade. Introduction of direct-acting antivirals (DAAs) like sofosbuvir has rapidly reduced the prevalence of chronic hepatitis C. Some major points:
- Market value: Estimated at approximately $10 billion globally in 2022.
- Market players: Gilead Sciences remains the dominant manufacturer, holding around 80% of the market share in the U.S.
- Prescription trends: U.S. prescriptions for HCV therapies peaked in 2017 at over 250,000 annually; recent declines reflect declining incidence, treatment saturation, and competition.
Competitive Landscape
New entrants and generics have impacts on the pricing trajectory:
| Competitor |
Products |
Market Share (2022) |
Notes |
| Gilead Sciences |
Sovaldi, Harvoni |
80% |
Leading with patent protections |
| Merck |
Zepatier |
10% |
Alternative for certain patient groups |
| Generic manufacturers |
Sofosbuvir copies |
10% |
Increasingly present in emerging markets |
Regulatory Changes Impacting Market
- Patent expiration: Patent for Gilead’s sofosbuvir in the U.S. expires in 2029; currently patents protect the drug.
- Cost reduction initiatives: Several states and payers push for generic or biosimilar use, influencing market prices and access.
Price Trajectory and Projections
Current Pricing Landscape
- Wholesale Acquisition Cost (WAC): Approximately $1,000 per 400 mg tablet (as of Q4 2022).
- Average sales price (ASP): Slightly below WAC, around $950.
- Rebates and discounts: Payors and providers typically receive discounts, reducing effective prices.
Factors Influencing Price Trends
- Generic availability: Expected post-2029 patent expiry, with generics potentially priced below $300 per course.
- Market saturation: As treatment rates plateau, demand and pricing pressure intensify.
- Policy shifts: Increased negotiations by Medicaid and Medicare may lead to further discounts.
Price Projections (Next 5 Years)
| Year |
Estimated Price per 400 mg Tablet |
Influencing Factors |
| 2023 |
$950 |
Stable, with ongoing rebates |
| 2024 |
$900 |
Slight downward pressure from negotiations |
| 2025 |
$850 |
Increased generic competition anticipated |
| 2026 |
$700 |
Growing generic market penetration |
| 2027 |
$500 |
Patent expiration approaches, biosimilar entry begins |
| 2028 |
$350 |
Multiple generic versions available |
Note: These projections assume no new form factors or synergistic therapies alter pricing dynamics.
Market Drivers and Risks
Drivers
- Increasing diagnosis and treatment of hepatitis C.
- Expanding use among underserved and high-risk populations.
- Policy mandates for treatment access.
Risks
- Emergence of novel therapies with better efficacy or safety profiles.
- Legal or patent disputes delaying generic competition.
- Changes in reimbursement policies reducing profit margins.
Key Takeaways
- NDC 69452-0395 (Sovaldi) remains the primary branded sofosbuvir product in the U.S.
- The market is mature, with declining demand and pricing pressure driven by patent expirations.
- Present prices are around $950 per tablet; generics are projected to reduce costs substantially after 2029.
- Competition and policy changes may accelerate price declines.
- The treatment landscape is likely to see shifts toward more cost-effective options, especially in emerging markets.
FAQs
-
When will generics of sofosbuvir become widely available?
Post-2029, once Gilead’s patent expires, generics are expected to enter the market, likely reducing prices significantly.
-
Are there alternative treatments with higher efficacy?
Current DAAs, including sofosbuvir-based therapies, have high cure rates (>95%). New formulations or drug combinations may emerge, but sofosbuvir retains a leading role.
-
What impact will policy changes have on prices?
Negotiations, especially by government payers, could lead to further discounts and accelerated generic adoption.
-
How are biosimilars influencing the market?
Biosimilars are unlikely for sofosbuvir, as it is a small-molecule drug, but generic copies are disrupting pricing.
-
Is pricing steady or declining now?
Prices are relatively steady but trending downward due to market saturation, negotiations, and impending patent expiry.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] Gilead Sciences. (2023). Product Sales and Market Share.
[3] U.S. Food and Drug Administration (FDA). (2022). Patent and Exclusivity Data.
[4] Health Affairs. (2021). Impact of Patent Expirations on Drug Prices.
[5] CDC. (2022). HCV Testing and Treatment Trends.
